Breaking Down NovoCure: 4 Analysts Share Their Views

Jul 2, 2024 · Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $23.0, a high estimate of $28.00, and a low estimate of …

$23
OFF

Breaking Down NovoCure: 4 Analysts Share Their Views

2 weeks from now

Jul 2, 2024 · Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $23.0, a high estimate of $28.00, and a low estimate of …

nasdaq.com

$22
OFF

Beyond The Numbers: 4 Analysts Discuss NovoCure Stock

2 weeks from now

Jul 26, 2024 · Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $22.0, along with a high estimate of $24.00 and a low estimate …

nasdaq.com

$28
OFF

Deep Dive Into NovoCure Stock: Analyst Perspectives (4 Ratings)

2 weeks from now

Oct 16, 2024 · Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $28.0, a high estimate of $40.00, and a low estimate of …

nasdaq.com

49%
OFF

Novocure Launches 49% After Pancreatic Cancer Treatment …

2 weeks from now

Dec 2, 2024 · Wedbush analyst David Nierengarten, on the other hand, says the results aren't strong enough to give Novocure an edge in market share. Overall, the device and two-drug …

investors.com

$24.25
OFF

Breaking Down Liquidia: 4 Analysts Share Their Views

2 weeks from now

5 days ago · Insights from analysts' 12-month price targets are revealed, presenting an average target of $24.25, a high estimate of $30.00, and a low estimate of $19.00.

nasdaq.com

$4
OFF

Breaking Down Quantum-Si: 4 Analysts Share Their Views

2 weeks from now

1 day ago · Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $4.0, a high estimate of $5.50, and a low estimate of $1.00.

nasdaq.com

FAQs about Breaking Down NovoCure: 4 Analysts Share Their Views Coupon?

How do analysts evaluate Novocure?

Price Targets: Analysts predict movements in price targets, offering estimates for NovoCure's future value. Examining the current and prior targets offers insights into analysts' evolving expectations. Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into NovoCure's market standing. ...

Does Novocure have an upward trend?

This upward trend is apparent, with the current average reflecting a 11.11% increase from the previous average price target of $18.00. An in-depth analysis of recent analyst actions unveils how financial experts perceive NovoCure. ...

Why do analysts'maintain' or 'raise' their stance on Novocure?

Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NovoCure. ...

Are Novocure insiders buying or selling more stock?

In the past three months, NovoCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,863.00 in company stock. Only 6.29% of the stock of NovoCure is held by insiders. 84.61% of the stock of NovoCure is held by institutions. ...

Should I buy Novocure Right Here?

Cramer: "Novocure: I think it should be bought right here. I do not understand why people have turned away from companies in health care in general. Novocure has a revolutionary device that can be used for multiple different areas against cancer. ...

What is Novocure's news sentiment?

NovoCure has a news sentiment score of 1.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies. ...